Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group.

Accepted/In Press date: 3 May 2022

e-pub ahead of print date: 28 June 2022

Published date: 28 June 2022

Additional Information: Funding Information: E.V.M reports consultant/advisor fees, speaker honoraria and or, research funding from AgNovos, Amgen, Consilient Healthcare, Fresenius Kabi, Gedeon Richter, Internis, Lilly, Novartis, ObsEva, Synexus and UCB, all outside the submitted work. E.M.C. reports lecture fees and travel support from Eli Lilly, Pfizer and UCB, outside the submitted work. N.C.H. reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare and Internis Pharma, outside the submitted work. J.A.K. reports a grant from UCB, outside the submitted work. He is the architect of FRAX® but has no financial interest. C.C. reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work. B.A. reports grants and personal fees from UCB, personal fees from Amgen, grants from Novartis, grants and personal fees from Pharma-cosmos, grants and personal fees from Kyowa Kirin, personal fees for Gedeon Richter outside the submitted work. BA also serves on the NovoNordisk Foundation Grants Committee on Endocrinology and Metabolism. M.L. reports lecture fees from Amgen, Astellas, Lilly, Meda, Renapharma and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health, outside the submitted work. D.P-A. reports institutional receipt of speaker fees from AMGEN and UCB Biopharma; consultancy fees from UCB Biopharma; research grants from UCB, Amgen, and Les Laboratoires Servier, all outside of the submitted work. J. A. reports grants and personal fees from Amgen outside the submitted work, grants from Radius and has been an advisor to Gilead and is part of their speaker’s bureau, outside the submitted work. F.B. is employed and is a shareholder in Quantify Research, a health economic research consultancy, outside of the submitted work. O.B. reports grant support from IBSA, MSD, Nutraveris, Novartis, Pfizer, Rottapharm, Servier and Theramex; consulting or lecture fees from Bayer, Genevrier, IBSA, Rottapharm, Servier, SMB and TRB Chemedica; all outside the submitted work. All other authors have no relevant conflicts of interest in relation to the submitted work. Funding Information: This position paper was prepared by the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group and has been endorsed by the International Osteoporosis Foundation. We are grateful for administrative support from Dr Dominique Pierroz. Funding Information: Work informing this project was supported by the UK Medical Research Foundation (MRF-145–0011-DG-HARV-C0913). N.C.H., E.M.C., E.M.D. and C.C. are supported by the UK Medical Research Council (MC_PC_21003; MC_PC_21001). Publisher Copyright: © 2022, The Author(s).

Keywords: Cost-effectiveness, FRAX, Fracture risk, Screening, Treatment

Local EPrints ID: 468276

URI: http://eprints.soton.ac.uk/id/eprint/468276

DOI: doi:10.1007/s11657-022-01117-6

ISSN: 1862-3522

PURE UUID: 15304355-8b26-489a-91a4-954da0f2e250

ORCID for Nicholas Harvey: orcid.org/0000-0002-8194-2512

ORCID for Cyrus Cooper: orcid.org/0000-0003-3510-0709

ORCID for Elizabeth Curtis: orcid.org/0000-0002-5147-0550

ORCID for Elaine Dennison: orcid.org/0000-0002-3048-4961

ORCID for Kate Ward: orcid.org/0000-0001-7034-6750

Date deposited: 09 Aug 2022 16:40

Last modified: 18 Mar 2024 03:38